Work

Antidrug Antibodies in Patients Treated with Alirocumab

Year: 2017

Type: letter

Abstract: In 10 clinical trials involving 4747 patients, among those who received the PCSK9 inhibitor alirocumab, antidrug antibodies developed in 5.1%, although no significant effect was seen on the reduction in LDL cholesterol levels.

Source: New England Journal of Medicine

DOI: 10.1056/nejmc1616623

Authors: Eli M. Roth, Anne C. Goldberg, Alberico L. Catapano, Albert Torri, George D. Yancopoulos, Neil Stahl, Aurélie Brunet, Guillaume Lecorps, Helen M. Colhoun

Institutions: Sterling Research Group, Washington University in St. Louis, University of Milan, MultiMedica, Regeneron (United States), Sanofi (United States), Sanofi (France), University of Edinburgh

Language: English

Topic: Lipoproteins and Cardiovascular Health

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W2596887658

Cites: 4

Cited by: 90

Related to: 10